# Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

> **NCT01024998** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 19 (actual)

## Conditions studied

- Macular Degeneration
- Age-Related Maculopathies
- Age-Related Maculopathy
- Maculopathies, Age-Related
- Maculopathy, Age-Related
- Retinal Degeneration
- Retinal Neovascularization
- Gene Therapy
- Therapy, Gene
- Eye Diseases

## Interventions

- **BIOLOGICAL:** AAV2-sFLT01
- **BIOLOGICAL:** AAV2-sFLT01
- **BIOLOGICAL:** AAV2-sFLT01
- **BIOLOGICAL:** AAV2-sFLT01

## Key facts

- **NCT ID:** NCT01024998
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-11
- **Primary completion:** 2014-07
- **Final completion:** 2018-07
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01024998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01024998, "Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01024998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*